Skip to main content
Home

Top menu InfoLep

  • About InfoLep

Main navigation

  • Home
  • Leprosy [5]
    • Global and Regional Leprosy Situation
    • WHO Global Leprosy Strategy
    • ILEP Strategy
    • World Leprosy Day 2022
    • Leprosy journals
  • Key topics [7]
    • Leprosy and COVID-19
    • Diagnostic tests
    • Prevention of leprosy [2]
      • Interventions to reduce transmission: post-exposure prophylaxis (PEP) [3]
        • LPEP Programme
        • PEP++ project
        • PEP4LEP project
      • Interventions to reduce transmission: vaccines
    • Rehabilitation & prevention of disability [2]
      • Preventing leprosy-related disabilities in girls and boys
      • Self-care in leprosy
    • Antimicrobial resistance in leprosy
    • Stigma, discrimination & mental wellbeing [4]
      • World Leprosy Day 2022
      • Gender
      • Mental wellbeing
      • SARI Project
    • Bioarchaeology of leprosy
  • Toolkits [5]
    • Guides on Stigma and Mental Wellbeing [5]
      • Guide 1. What are health-related stigma and mental wellbeing? [8]
        • 1. What is stigma?
        • 2. Why does stigma exist?
        • 3. What are the causes of stigma?
        • 4. Who stigmatises?
        • 5. How does it feel to experience stigma?
        • 6. What are the effects of stigma?
        • 7. Effects of stigma and discrimination on mental wellbeing
        • Annex Guide 1
      • Guide 2. How to reduce the impact of stigma [7]
        • 1. From undetected disease to diagnosis to support
        • 2. Individual-level interventions
        • 3. Group-level interventions
        • 4. Family-level interventions
        • 5. Referral
        • 6. Further reading
        • Annexes Guide 2
      • Guide 3. How to reduce sources of stigma [6]
        • 1. Background to the design of a stigma-reduction intervention
        • 2. Identifying the sources of stigma
        • 3. Targeting an intervention
        • 4. Inclusion of affected persons and champions in interventions
        • 5. Interventions by source type
        • Annexes Guide 3
      • Guide 4. How to assess health-related stigma and mental wellbeing [9]
        • 1. What is the purpose of the assessment?
        • 2. What approach would best fit your purpose and context?
        • 3. Quantitative assessment methods
        • 4. Qualitative assessment methods
        • 5. Assessments using mixed methods
        • 6. Developing qualitative methods from scratch
        • 7. How do you conduct a stigma assessment?
        • 8. How to interpret and report your findings
        • Annexes Guide 4
      • Glossary
    • NTD Morbidity and Disability Toolkit [15]
      • CHIEF
      • Clinical Profile
      • EMIC affected persons
      • EMIC-CS Community Stigma
      • Participation Scale
      • Patient Health Questionnaire (PHQ-9)
      • 5-Question Stigma Indicators
      • Salsa Scale
      • SARI Stigma Scale
      • SDS Social Distance Scale
      • SRQ Self-reporting Questionnaire
      • Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
      • WGQ Washington Group Questions
      • WHODAS
      • WHOQOL-BREF
    • Perception Study Toolkit (PST)
    • Zero Leprosy Toolkit
    • CBM's Community Mental Health Good Practice Guides
  • Publications
  • Organizations

Top menu - mobile infoLep

  • About InfoLep

Search

Refine your results

Refine your results


Selected filters

  • Reset filters
  • English
  • Leprosy (Hansen disease)
  • Minocycline - MINO

Filter by type

  • Publications only

NTD

  • (-) Leprosy (Hansen disease) (21)

Subject

  • Clarithromycin - CLARI (11)
  • Dapsone (2)
  • (-) Minocycline - MINO (21)
  • Moxifloxacin (3)
  • Ofloxacin - OFLO (19)
  • Rifampicin - RMP (10)
  • Rifapentine - RPT (2)
  • Multi-drug therapy (MDT) (8)
  • Complications and reactions (1)
  • Epidemiology (1)
  • Treatment (11)
  • Drug resistance (1)

Publication Type

  • Article (19)
  • Full text online (15)
  • Letter to the editor (2)

Journal

  • American journal of clinical and experimental medicine (1)
  • Anais brasileiros de dermatologia (1)
  • Antimicrobial agents and chemotherapy (3)
  • Clinical pharmacology : advances and applications (1)
  • European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (1)
  • Hong Kong Dermatology & Venereology Bulletin (1)
  • Indian journal of dermatology, venereology and leprology (1)
  • Indian journal of leprosy (2)
  • International journal of dermatology (1)
  • International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association (2)
  • Journal of global antimicrobial resistance (1)
  • Journal of the Indian Medical Association (1)
  • Leprosy review (4)
  • Tropical Medicine & International Health (1)

Year of Publication

  • 2022 (1)
  • 2020 (2)
  • 2017 (2)
  • 2015 (1)
  • 2011 (2)
  • 2008 (1)
  • 2006 (2)
  • 2001 (1)
  • 2000 (3)
  • 1999 (1)
  • 1997 (2)
  • 1996 (1)
  • 1994 (1)
  • 1992 (1)

Language

  • (-) English (21)

Regional focus

  • European Region (EUR) (1)
    • France (1)
  • Region of the Americas (AMR) (1)
    • Brazil (1)
  • South-East Asia Region (SEAR) (4)
    • India (3)
    • Indonesia (1)
    • Nepal (1)
  • Western Pacific Region (WPR) (1)
    • Hong Kong (China) (1)
 
  • Relevance
  • Date
21 items

Publication

Single-lesion paucibacillary leprosy: a retrospective study of 75 cases treated with the ROM scheme.

Pennini SN, França J, Rebello P, et al. Anais brasileiros de dermatologia. 2022;
Download PDF

Publication

Analysis of bacteriological Index between fixed multidrug therapy and new WHO recommended alternative regimen with ofloxacin, minocycline and clofazimine of rifampicin resistant cases from the hospitals of The Leprosy Mission, India.

Lavania M, Darlong J, Singh I, et al. Journal of global antimicrobial resistance. 2020;
Download PDF

Publication

Treatment of histoid leprosy: a lack of consensus.

Bartos G, Sheuring R, Combs A, et al. International journal of dermatology. 2020;

Publication

Interleukin-12 and Interleukin-4 Levels of Multibacillary Leprosy Patients Before and After Rifampicine Ofloxacine Minocycline Combined Therapy

Budhiani S, Muchtar SV, Amin S. American journal of clinical and experimental medicine . 2017; 5 (4) : 134-137.
Download PDF

Publication

Adverse reactions in leprosy patients who underwent dapsone multidrug therapy: a retrospective study.

Guragain S, Upadhayay N, Bhattarai BM. Clinical pharmacology : advances and applications. 2017;
Download PDF

Publication

A randomized controlled trial to compare cure and relapse rate of paucibacillary multidrug therapy with monthly rifampicin, ofloxacin, and minocycline among paucibacillary leprosy patients in Agra District, India.

Kumar A, Girdhar A, Girdhar BK. Indian journal of dermatology, venereology and leprology. 2015; 81 (4) : 356-62.
Download PDF

Publication

Is there a role for rifampicin, ofloxacin and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and meta-analysis

Setia M, Shinde S, Jerajani H, et al. Blackwell Science. Tropical Medicine & International Health. 2011; 16 (12) : 1541–51.
Download PDF

Publication

A randomised controlled trial assessing the effect of adding clarithromycin to rifampicin, ofloxacin and minocycline in the treatment of single lesion paucibacillary leprosy in Agra District, India.

Girdhar A, Kumar A, Girdhar BK. Leprosy review. 2011; 82 (1) : 46-54.
Download PDF

Publication

Long term follow-up results of 1 year MDT in MB leprosy patients treated with standard MDT + once a month Minocycline and Ofloxacin.

Katoch K, Katoch V M, Natarajan M, et al. Indian journal of leprosy. 2008; 80 (4) : 331-44.

Publication

Evaluation of a new fixed duration (12 weeks) multi-drug regimen of bactericidal drugs in multibacillary leprosy.

Tejasvi T, Khaitan B K, Khanna N, et al. Indian journal of leprosy. 2006; 78 (4) : 329-37.

Publication

Multidrug therapy in leprosy.

Manglani P R, Arif M A. Journal of the Indian Medical Association. 2006; 104 (12) : 686-8.

Publication

Newer drugs in leprosy.

Grosset J H. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association. 2001; 69 (2 Suppl) : S14-8.
Download PDF

Publication

Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice.

Consigny S, Bentoucha A, Bonnafous P, et al. Antimicrobial agents and chemotherapy. 2000; 44 (10) : 2919-21.
Download PDF

Publication

Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy.

Ji B, Grosset J. Leprosy review. 2000;
Download PDF

Publication

Field trials of a single dose of the combination rifampicin-ofloxacin-minocycline (ROM) for the treatment of paucibacillary leprosy.

Gupte M D. Leprosy review. 2000;
Download PDF

Publication

Leprosy - A Review

Hong Kong Dermatology & Venereology Bulletin. 1999; 7 (2) : 65 - 70.
Download PDF

Publication

Experimental evaluation of possible new short-term drug regimens for treatment of multibacillary leprosy.

Banerjee D K, McDermott-Lancaster R D, McKenzie S. Antimicrobial agents and chemotherapy. 1997; 41 (2) : 326-30.
Download PDF

Publication

Rifampicin/minocycline and ofloxacin (ROM) for single lesions--what is the evidence?

Lockwood DN. Leprosy review. 1997; 68 (4) : 299-300.
Download PDF

Publication

Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice.

Ji B, Perani E G, Petinom C, et al. Antimicrobial agents and chemotherapy. 1996; 40 (2) : 393-9.
Download PDF

Publication

Chemotherapy of lepromatous leprosy: recent developments and prospects for the future.

Gelber R H. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 1994; 13 (11) : 942-52.

Pagination

  • Current page 1
  • Page 2
  • Next page Next ›
  • Last page Last »

Use Ris for EndNote, Mendeley, RefWorks, Zotero and most other reference management software.

Quick links

  • Leprosy
  • Key topics
  • Toolbox
  • Publications
  • Organizations

Support

  • Contact
  • Privacy statement
  • Contact
  • FAQ

Contact us

info@infolep.org

(+31) 20 595 0500

     

Stay up to date with the latest publications and news related to leprosy.

Subscribe to newsletter

Related websites:

  • infontd

© 2022 InfoNTD